Terminons l’interdiction sur la recherche en matière de substances psychoactives

Cette étude scientifique évalue le rôle de la LSD, la marijuana et l’ecstasy pour soulager les troubles psychiatriques.

Pour en savoir plus, veuillez lire les informations ci-dessous (en anglais).

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.


A few privately funded studies of these compounds have yielded tantalizing hints that some of these ideas merit consideration. Yet doing this research through standard channels, as psychopharmacologist David J. Nutt of Imperial College London and his co-authors noted in a recent article in Nature Reviews Neuroscience, requires traversing a daunting bureaucratic labyrinth that can dissuade even the most committed investigator. (Scientific American is part of Nature Publishing Group.) It can take years to receive approval for a clinical trial from both regulators and hospital ethics committees, even while tallying thousands of dollars in licensing fees and tens of thousands to obtain drugs that are, of course, unavailable from a chemical supply catalogue.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Financé par des subventions de

Open Society Foundations Robert Carr Fund

© 2019 International Drug Policy Consortium